Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial

A major challenge for HIV vaccine development is to raise anti-envelope antibodies capable of recognizing and neutralizing diverse strains of HIV-1. Accordingly, a full length single chain (FLSC) of gp120-CD4 chimeric vaccine construct was designed to present a highly conserved CD4-induced (CD4i) HI...

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Joel V., Davis, Charles, Husson, Jennifer S., Nelson, Amy, Prado, Ilia, Flinko, Robin, Lam, Ka Wing J., Mutumbi, Lydiah, Mayer, Bryan T., Dong, Dan, Fulp, William, Mahoney, Celia, Gerber, Monica, Gottardo, Raphael, Gilliam, Bruce L., Greene, Kelli, Gao, Hongmei, Yates, Nicole, Ferrari, Guido, Tomaras, Georgia, Montefiori, David, Schwartz, Jennifer A., Fouts, Timothy, DeVico, Anthony L., Lewis, George K., Gallo, Robert C., Sajadi, Mohammad M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224181/
https://www.ncbi.nlm.nih.gov/pubmed/34099328
http://dx.doi.org/10.1016/j.vaccine.2021.05.090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224181/
https://www.ncbi.nlm.nih.gov/pubmed/34099328
http://dx.doi.org/10.1016/j.vaccine.2021.05.090

Ejemplares similares